bioMerieux (OTCMKTS:BMXMF) Stock Rating Upgraded by Zacks Research

bioMerieux (OTCMKTS:BMXMF) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.

BMXMF has been the topic of a number of other research reports. Piper Sandler initiated coverage on shares of bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Morgan Stanley reissued an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th. Five research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, bioMerieux currently has an average rating of “Reduce”.

bioMerieux Price Performance

OTCMKTS BMXMF opened at $83.27 on Monday. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08. bioMerieux has a 52-week low of $77.00 and a 52-week high of $138.15. The company has a fifty day moving average of $82.98 and a 200-day moving average of $87.89.

bioMerieux Company Profile

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.